Qualigen Therapeutics, Inc. (QLGN) Financial Statements
Industry: Finance Services
In fiscal 2025, Qualigen Therapeutics reported revenue of $0. Net income was -$17.0M, or -$8.11 per diluted share. Operating activities generated -$7.0M of cash. At fiscal year end, Qualigen Therapeutics held $31.3M in total assets against $3.3M in total liabilities, including $19.3M of cash and equivalents.
Open the full interactive Qualigen Therapeutics financials → Quarterly statements, key ratios, valuation history and price charts.
Qualigen Therapeutics Key Stats
| Share Price | $1.45 |
|---|---|
| Market Cap | $29.4M |
| 52-Week Range | $0.65 – $4.01 |
| Shares Outstanding | 20.3 million (basic, 2026 Q2) |
Qualigen Therapeutics Income Statement
| FY 2019 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Revenue | $0 | $5.7M | $5.0M | $0 | $0 | $0 |
| Cost of Goods Sold | — | $113,000 | — | — | — | — |
| Gross Profit | — | $689,236 | — | — | — | — |
| Operating Income | -$10.8M | -$22.7M | -$22.2M | -$11.3M | -$5.8M | -$13.2M |
| Pre-Tax Income | -$10.1M | -$17.9M | -$21.3M | -$12.5M | -$6.2M | -$17.0M |
| Income Tax | — | $5,427 | -$265,074 | -$4,793 | $6,334 | $0 |
| Net Income | -$10.1M | -$17.9M | -$18.6M | -$13.4M | -$6.3M | -$17.0M |
| Diluted EPS | -$530.00 | -$305.00 | — | -$132.25 | -$17.55 | -$8.11 |
Qualigen Therapeutics Quarterly Results
| 2025 Q3 | 2025 Q4 | 2026 Q1 | 2026 Q2 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| Net Income | -$2.0M | -$10.6M | -$6.1M | -$4.2M |
| Diluted EPS | -$4.68 | -$4.40 | -$0.79 | -$0.21 |
Qualigen Therapeutics Balance Sheet
| FY 2019 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash & Equivalents | $1.7M | — | — | — | $1.2M | $19.3M |
| Current Assets | $2.2M | $20.8M | $10.8M | $1.2M | $4.7M | $31.0M |
| Total Assets | $2.8M | $22.8M | $19.1M | $2.0M | $4.7M | $31.3M |
| Current Liabilities | $1.7M | $4.6M | $8.6M | $4.1M | $2.0M | $3.3M |
| Total Long-Term Debt | — | — | $60,197 | $1.3M | — | — |
| Total Liabilities | $1.7M | $6.3M | $10.3M | $4.1M | $2.0M | $3.3M |
| Shareholders' Equity | $1.1M | $16.6M | $7.2M | -$2.1M | $2.7M | $28.0M |
Qualigen Therapeutics Cash Flow Statement
| FY 2019 | FY 2021 | FY 2022 | FY 2023 | FY 2024 | FY 2025 | |
|---|---|---|---|---|---|---|
| Cash From Operations | -$14.5M | -$14.7M | -$13.2M | -$10.3M | -$6.3M | -$7.0M |
| Cash From Investing | $7.0M | -$141,364 | -$183,763 | $4.2M | -$1.9M | -$15.9M |
| Cash From Financing | $1.4M | $8.4M | $2.9M | -$550,000 | $9.0M | $41.0M |
| Free Cash Flow | -$14.5M | -$14.9M | -$13.4M | -$10.3M | — | — |
Figures from Qualigen Therapeutics' 10-K and 10-Q filings with the SEC, as of 2026-10-14. Fiscal years follow the company's own reporting calendar. EPS and share counts are adjusted for later stock splits. See the full Qualigen Therapeutics financials page for every line item.
Qualigen Therapeutics Company Profile
| Ticker | QLGN |
|---|---|
| Exchange | Nasdaq |
| Industry | Finance Services |
| Headquarters | El Segundo, California |
| Incorporated in | Delaware |
| Fiscal Year End | December 31 |
| SEC Filer Category | Non-accelerated filer, smaller reporting company |
| SEC CIK | 0001460702 |
Frequently Asked Questions
What was Qualigen Therapeutics' revenue in fiscal 2025?
Qualigen Therapeutics (QLGN) reported revenue of $0 for fiscal 2025.
What is Qualigen Therapeutics' annual revenue history?
Qualigen Therapeutics' annual revenue by fiscal year: 2019: $0; 2021: $5.7M; 2022: $5.0M; 2023: $0; 2024: $0; 2025: $0.
What was Qualigen Therapeutics' net income in fiscal 2025?
Qualigen Therapeutics reported net income of -$17.0M for fiscal 2025.
What was Qualigen Therapeutics' earnings per share (EPS) in fiscal 2025?
Qualigen Therapeutics' diluted EPS was -$8.11 for fiscal 2025 (adjusted for any later stock splits).
What was Qualigen Therapeutics' revenue last quarter?
In its most recent reported quarter (2026 Q2), Qualigen Therapeutics reported revenue of $0.
How many shares of Qualigen Therapeutics are outstanding?
Qualigen Therapeutics reported a weighted average of 20.3 million basic shares outstanding in 2026 Q2.
What is Qualigen Therapeutics' market cap?
Based on its latest closing price, Qualigen Therapeutics (QLGN) has a market capitalization of about $29.4M.
When does Qualigen Therapeutics' fiscal year end?
Qualigen Therapeutics' fiscal year end, as registered with the SEC, is December 31.
Where is Qualigen Therapeutics headquartered?
Qualigen Therapeutics lists its business address in El Segundo, California in its SEC filings.